|
VIRGIL - European Vigilance Network for the Management of Antiviral Drug Resistance (FP6-LIFESCIHEALTH) (2004-05-01 - 2008-04-30)
(»add to infobox)
 
|
Fabien ZOULIM,
Bruno LINA,
Michael P. MANNS,
Jean-Michel PAWLOTSKY,
Maria ZAMBON,
Ralf BARTENSCHLAGER,
Alan HAY,
Gerd R. PAPE,
Stephan LUDWIG,
Johan NEYTS,
Willy SPAAN,
Patricia NOVELLI,
Jean Marie COHEN,
Solko Walle SCHALM,
Alfredo ALBERTI,
Maria BUTI FERRET,
Xavier FORNS,
Georgios GERMANIDIS,
David MUTIMER,
Francesco NEGRO,
Anna PODHAJSKA,
Etienne SOKAL,
Vincent SORIANO,
Howard THOMAS,
Stefan ZEUZEM,
Isabella DONATELLI,
Sylvie VAN DER WERF,
Oliver PLANZ,
Hans Dieter KLENK,
Juan ORTIN,
Robertus Wouterus Hermanus RUIGROK,
Hubert E. BLUM,
Helena DANIELSON,
Luca GUIDOTTI,
Joerg PETERSEN,
Felix REY,
Nicole ZITZMANN,
Stephan PLESCHKA,
Thorsten WOLFF,
Carlo FERRARI,
Thomas BERG,
Matti SAELLBERG,
Mark THURSZ,
Teresa SANTANTONIO,
Juerg REICHEN,
Anders VAHLNE,
Gerhard PÜRSTINGER,
Luc BARRAUD,
Guy VERNET,
Avidan Uriel NEUMANN,
Derek SMITH,
William John PAGET,
Jerome WEINBACH,
Massimo LEVRERO,
Geneviève INCHAUSPE,
Christophe COMBET
|
|
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR716 - Rhône) (France),
UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France),
MEDIZINISCHE HOCHSCHULE HANNOVER (DE929 - Region Hannover) (Germany),
UNIVERSITE PARIS XII - VAL DE MARNE (FR107 - Val-de-Marne) (France),
HEALTH PROTECTION AGENCY (UKI11 - Inner London - West) (Great Britain),
UNIVERSITAETSKLINIKUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany),
MEDICAL RESEARCH COUNCIL (UKI11 - Inner London - West) (Great Britain),
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany),
UNIVERSITAETSKLINIKUM DUESSELDORF (DEA11 - Düsseldorf, Kreisfreie Stadt) (Germany),
KATHOLIEKE UNIVERSITEIT LEUVEN (BE242 - Arr. Leuven) (Belgium),
AKADEMISCH ZIEKENHUIS LEIDEN - LEIDEN UNIVERSITAIR MEDISCH CENTRUM (NL331 - Agglomeratie Leiden en Bollenstreek) (Netherlands),
RETROSCREEN VIROLOGY LTD (UKI11 - Inner London - West) (Great Britain),
ORGANIZE AND PROMOTE EPIDEMIOLOGICAL NETWORKS / RESEAUX D'OBSERVATION DES MALADIES ET DES EPIDEMIES (FR101 - Paris) (France),
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL335 - Groot-Rijnmond) (Netherlands),
ISTITUTO VENETO DI MEDICINA MOLECULARE (VIMM) - CENTRO DI RECERCA DELLA FONDAZIONE PER LA RICRECA BIOMEDICA AVANZATA - ONLUS (ITD36 - Padova) (Italy),
HOSPITAL UNIVERSITARI VALL D'HEBRON (ES511 - Barcelona) (Spain),
HOSPITAL CLINIC I PROVINCIAL DE BARCELONA (ES511 - Barcelona) (Spain),
PAPAGEORGIOU GENERAL HOSPITAL (GR122 - Thessaloniki) (Greece),
THE UNIVERSITY OF BIRMINGHAM (UKG31 - Birmingham) (Great Britain),
UNIVERSITE DE GENEVE (CH012 - Valais) (Switzerland),
UNIWERSYTET GDANSKI (PL633 - Gdansk-Gdynia-Sopot) (Poland),
UNIVERSITE CATHOLIQUE DE LOUVAIN (BE310 - Arr. Nivelles) (Belgium),
ASOCIACION INVESTIGACION Y EDUCATION EN SIDA - HOSPITAL CARLOS III (ES300 - Madrid) (Spain),
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain),
UNIVERSITAET DES SAARLANDES (DEC01 - Stadtverband Saarbrücken) (Germany),
ISTITUTO SUPERIORE DI SANITA (ITE43 - Roma) (Italy),
INSTITUT PASTEUR (FR101 - Paris) (France),
FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSANSTALT FUER VIRUSKRANKHEITEN DER TIERE (DE801 - Greifswald, Kreisfreie Stadt) (Germany),
PHILIPPS UNIVERSITAET MARBURG (DE724 - Marburg-Biedenkopf) (Germany),
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES300 - Madrid) (Spain),
UNIVERSITE JOSEPH FOURIER GRENOBLE 1 (FR714 - Isère) (France),
UNIVERSITAETSKLINIKUM FREIBURG (DE131 - Freiburg im Breisgau, Stadtkreis) (Germany),
UPPSALA UNIVERSITET (SE021 - Uppsala län) (Sweden),
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR (ITC45 - Milano) (Italy),
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (DE600 - Hamburg) (Germany),
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (France),
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain),
CREATIS GMBH (DE724 - Marburg-Biedenkopf) (Germany),
ROBERT KOCH-INSTITUT (DE300 - Berlin) (Germany),
AZIENDA OSPEDALIERA DI PARMA (IT402 - Parma) (Italy),
CHARITE - UNIVERSITAETSMEDIZIN BERLIN (DE300 - Berlin) (Germany),
KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden),
RIOTECH PHARMACEUTICALS LIMITED (UKI11 - Inner London - West) (Great Britain),
UNIVERSITA DEGLI STUDI DI BARI (ITF42 - Bari) (Italy),
UNIVERSITAET BERN (CH033 - Aargau) (Switzerland),
TRIPEP AB (SE010 - Stockholms län) (Sweden),
UNIVERSITAET INNSBRUCK (AT332 - Innsbruck) (Austria),
BIOALLIANCE PHARMA (FR101 - Paris) (France),
BIOMERIEUX SA (FR716 - Rhône) (France),
BAR ILAN UNIVERSITY (NoRegion - NoRegion) (Israel),
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE (UKH12 - Cambridgeshire CC) (Great Britain),
STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG (NL310 - Utrecht) (Netherlands),
INSERM - TRANSFERT SA (FR101 - Paris) (France),
FOUNDATION "ANDREA CESALPINO" (ITE43 - Roma) (Italy),
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France) |
| BUDGET: | 17.072.000 € |
| FUNDING: | 9.000.000 € |
| INSTRUMENT: | |
| PROGRAMME: | FP6-LIFESCIHEALTH |
|
|
|
The overall objective of the viRgil Network of Excellence is to set up the first-ever European Vigilance Network capable of addressing current and emerging antiviral drugs resistance developments. Focusing first on three major diseases (influenza and viral hepatitis B and C), our strategy is to build a sustainable, patient-oriented 'virtual institute' by integrating the currently fragmented European capacities into interacting platforms that together will allow the containment of the problem of viral drug resistance. Being approach- rather than virus- based, the integration process will be flexible enough to embrace in the future drug resistance problems related to other human viruses. Indeed, the proposed complementary platforms will focus each on a topic contributing towards broad objectives: the setting-up of the viRgil clinical platforms (surveillance and virology) will allow a global approach for monitoring, testing and ultimately improving the management of antiviral drug resistance in treated patients, leading to outstanding practices and standards in Europe. Attention will be paid to specific patient communities (children, women). These activities will be strengthened by knowledge generated from the in vitro and in vivo models platform, which will elucidate the mechanisms of the the development of resistance, and from the host determinants platform aiming at understanding patient-related (immune/genetic) factors conditioning viral drug resistance. Platforms dedicated to drugs and pharmacological aspects as well as innovation and technology will enable to anticipate viral resistance against promising drugs closed to clinical application and to overcome future resistance problems by proposing more rational approaches for drug development to the private sector and effective tools for testing resistance to the clinicians. Lastly, viRgil objectives and the benefit for the community will be constantly evaluated by the societal impact platforrm.
|
| PERSONS (56/56) |
|
Fabien ZOULIM (Contact / INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR716 - Rhône) (France))
Bruno LINA (Contact / UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France))
Michael P. MANNS (Contact / MEDIZINISCHE HOCHSCHULE HANNOVER (DE929 - Region Hannover) (Germany))
Jean-Michel PAWLOTSKY (Contact / UNIVERSITE PARIS XII - VAL DE MARNE (FR107 - Val-de-Marne) (France))
Maria ZAMBON (Contact / HEALTH PROTECTION AGENCY (UKI11 - Inner London - West) (Great Britain))
Ralf BARTENSCHLAGER (Contact / UNIVERSITAETSKLINIKUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany))
Alan HAY (Contact / MEDICAL RESEARCH COUNCIL (UKI11 - Inner London - West) (Great Britain))
Gerd R. PAPE (Contact / LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany))
Stephan LUDWIG (Contact / UNIVERSITAETSKLINIKUM DUESSELDORF (DEA11 - Düsseldorf, Kreisfreie Stadt) (Germany))
Johan NEYTS (Contact / KATHOLIEKE UNIVERSITEIT LEUVEN (BE242 - Arr. Leuven) (Belgium))
Willy SPAAN (Contact / AKADEMISCH ZIEKENHUIS LEIDEN - LEIDEN UNIVERSITAIR MEDISCH CENTRUM (NL331 - Agglomeratie Leiden en Bollenstreek) (Netherlands))
Patricia NOVELLI (Contact / RETROSCREEN VIROLOGY LTD (UKI11 - Inner London - West) (Great Britain))
Jean Marie COHEN (Contact / ORGANIZE AND PROMOTE EPIDEMIOLOGICAL NETWORKS / RESEAUX D'OBSERVATION DES MALADIES ET DES EPIDEMIES (FR101 - Paris) (France))
Solko Walle SCHALM (Contact / ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL335 - Groot-Rijnmond) (Netherlands))
Alfredo ALBERTI (Contact / ISTITUTO VENETO DI MEDICINA MOLECULARE (VIMM) - CENTRO DI RECERCA DELLA FONDAZIONE PER LA RICRECA BIOMEDICA AVANZATA - ONLUS (ITD36 - Padova) (Italy))
Maria BUTI FERRET (Contact / HOSPITAL UNIVERSITARI VALL D'HEBRON (ES511 - Barcelona) (Spain))
Xavier FORNS (Contact / HOSPITAL CLINIC I PROVINCIAL DE BARCELONA (ES511 - Barcelona) (Spain))
Georgios GERMANIDIS (Contact / PAPAGEORGIOU GENERAL HOSPITAL (GR122 - Thessaloniki) (Greece))
David MUTIMER (Contact / THE UNIVERSITY OF BIRMINGHAM (UKG31 - Birmingham) (Great Britain))
Francesco NEGRO (Contact / UNIVERSITE DE GENEVE (CH012 - Valais) (Switzerland))
Anna PODHAJSKA (Contact / UNIWERSYTET GDANSKI (PL633 - Gdansk-Gdynia-Sopot) (Poland))
Etienne SOKAL (Contact / UNIVERSITE CATHOLIQUE DE LOUVAIN (BE310 - Arr. Nivelles) (Belgium))
Vincent SORIANO (Contact / ASOCIACION INVESTIGACION Y EDUCATION EN SIDA - HOSPITAL CARLOS III (ES300 - Madrid) (Spain))
Howard THOMAS (Contact / IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain))
Stefan ZEUZEM (Contact / UNIVERSITAET DES SAARLANDES (DEC01 - Stadtverband Saarbrücken) (Germany))
Isabella DONATELLI (Contact / ISTITUTO SUPERIORE DI SANITA (ITE43 - Roma) (Italy))
Sylvie VAN DER WERF (Contact / INSTITUT PASTEUR (FR101 - Paris) (France))
Oliver PLANZ (Contact / FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSANSTALT FUER VIRUSKRANKHEITEN DER TIERE (DE801 - Greifswald, Kreisfreie Stadt) (Germany))
Hans Dieter KLENK (Contact / PHILIPPS UNIVERSITAET MARBURG (DE724 - Marburg-Biedenkopf) (Germany))
Juan ORTIN (Contact / CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES300 - Madrid) (Spain))
Robertus Wouterus Hermanus RUIGROK (Contact / UNIVERSITE JOSEPH FOURIER GRENOBLE 1 (FR714 - Isère) (France))
Hubert E. BLUM (Contact / UNIVERSITAETSKLINIKUM FREIBURG (DE131 - Freiburg im Breisgau, Stadtkreis) (Germany))
Helena DANIELSON (Contact / UPPSALA UNIVERSITET (SE021 - Uppsala län) (Sweden))
Luca GUIDOTTI (Contact / FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR (ITC45 - Milano) (Italy))
Joerg PETERSEN (Contact / UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (DE600 - Hamburg) (Germany))
Felix REY (Contact / CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (France))
Nicole ZITZMANN (Contact / THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain))
Stephan PLESCHKA (Contact / CREATIS GMBH (DE724 - Marburg-Biedenkopf) (Germany))
Thorsten WOLFF (Contact / ROBERT KOCH-INSTITUT (DE300 - Berlin) (Germany))
Carlo FERRARI (Contact / AZIENDA OSPEDALIERA DI PARMA (IT402 - Parma) (Italy))
Thomas BERG (Contact / CHARITE - UNIVERSITAETSMEDIZIN BERLIN (DE300 - Berlin) (Germany))
Matti SAELLBERG (Contact / KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden))
Mark THURSZ (Contact / RIOTECH PHARMACEUTICALS LIMITED (UKI11 - Inner London - West) (Great Britain))
Teresa SANTANTONIO (Contact / UNIVERSITA DEGLI STUDI DI BARI (ITF42 - Bari) (Italy))
Juerg REICHEN (Contact / UNIVERSITAET BERN (CH033 - Aargau) (Switzerland))
Anders VAHLNE (Contact / TRIPEP AB (SE010 - Stockholms län) (Sweden))
Gerhard PÜRSTINGER (Contact / UNIVERSITAET INNSBRUCK (AT332 - Innsbruck) (Austria))
Luc BARRAUD (Contact / BIOALLIANCE PHARMA (FR101 - Paris) (France))
Guy VERNET (Contact / BIOMERIEUX SA (FR716 - Rhône) (France))
Avidan Uriel NEUMANN (Contact / BAR ILAN UNIVERSITY (NoRegion - NoRegion) (Israel))
Derek SMITH (Contact / THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE (UKH12 - Cambridgeshire CC) (Great Britain))
William John PAGET (Contact / STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG (NL310 - Utrecht) (Netherlands))
Jerome WEINBACH (Contact / INSERM - TRANSFERT SA (FR101 - Paris) (France))
Massimo LEVRERO (Contact / FOUNDATION "ANDREA CESALPINO" (ITE43 - Roma) (Italy))
Geneviève INCHAUSPE ( / CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France))
Christophe COMBET ( / CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France))
| RELATED NAVIGATION AREA(S) (4/4) |
|
IFR 128
IFR 62
Infectiology
Testing anti-viral drug resistance and understanding resistance development
|
|
|
|
